Sildenafil increases diclofenac antinociception in the formalin test

European Journal of Pharmacology

Volumn 418, Issue 3, 2001, Pages 195-200

  Asomoza Espinosa, Raquel ^a   Alonso López, Rosario ^a   Mixcoatl Zecuatl, Teresa ^a   Aguirre Bañuelos, Patricia ^a   Torres López, Jorge E ^a,b   Granados Soto, Vinicio ^a,c  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b Div Academica Cie Salud Univ J   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Antinociception; cGMP; Diclofenac; Sildenafil; Synergism

Indexed keywords

CYCLIC GMP; DICLOFENAC; FORMALDEHYDE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HINDLIMB; NONHUMAN; NUCLEIC ACID METABOLISM; PRIORITY JOURNAL; RAT;

ANALGESICS; ANIMALS; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; FORMALDEHYDE; PAIN; PAIN MEASUREMENT; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; RATS; RATS, WISTAR;

EID: 0343338160     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(01)00956-6     Document Type: Article

References (30)

1. Aguirre-Bañuelos P., Granados-Soto V. Evidence for a peripheral mechanism of action for the potentiation of the antinociceptive effect of morphine by dipyrone. J. Pharmacol. Toxicol. Methods. 42:1999;79-85.
2. Aguirre-Bañuelos P., Granados-Soto V. Evidence for the participation of the nitric oxide-cyclic GMP pathway in the antinociceptive action of meloxicam in the formalin test. Eur. J. Pharmacol. 395:2000;9-13.
3. Aguirre-Bañuelos P., Castañeda-Hernández G., López-Muñoz F.J., Granados-Soto V. Effect of coadministration of caffeine and either adenosine agonists or cyclic nucleotides on ketorolac analgesia. Eur. J. Pharmacol. 377:1999;175-182.
4. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75:1995;725-745.
5. Boolell M., Gepi-Attee S., Gingell C.J.G., Price M.E., Tang K., Turner L.A., Naylor A.M. Sildenafil, a novel effective treatment for male erectile dysfunction. Br. J. Urol. 78:1996;257-261.
6. Duarte I.D.G., Lorenzetti B.B., Ferreira S.H. Peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway. Eur. J. Pharmacol. 186:1990;289-293.
7. Duarte I.D.G., Santos I.R., Lorenzetti B.B., Ferreira S.H. Analgesia by direct antagonism of nociceptor sensitization involves the arginine-nitric oxide-cGMP pathway. Eur. J. Pharmacol. 217:1992;225-227.
8. 2+ dependent process. Prostaglandins. 18:1979;179-190.
9. Ferreira S.H., Duarte I.D.G., Lorenzetti B.B. The molecular mechanism of action of peripheral morphine analgesia: stimulation of the cGMP system via nitric oxide release. Eur. J. Pharmacol. 201:1991;121-122.
10. Granados-Soto V., Flores-Murrieta F.J., Castañeda-Hernández G., López-Muñoz F.J. Evidence for the involvement of nitric oxide in the antinociceptive effect of ketorolac in the rat. Eur. J. Pharmacol. 277:1995;281-284.
11. Granados-Soto V., Rufino M.O., Gomes-Lopes L.D., Ferreira S.H. Evidence for the involvement of nitric oxide-cGMP pathway in the antinociception of morphine in the formalin test. Eur. J. Pharmacol. 287:1997;281-284.
12. Ethical guidelines for investigations on experimental pain in conscious animals. Pain. 16:1983;109-110.
13. Islas-Cadena M., Aguirre-Bañuelos P., Granados-Soto V. Evidence for the participation of the nitric oxide-cyclic GMP pathway in the antinociceptive effect of nimesulide. J. Pharmacol. Toxicol. Methods. 42:1999;87-92.
14. López-Muñoz F.J., Castañeda-Hernández G., Torres-López J.E., Picazo Y.F., Flores-Murrieta F.J., Granados-Soto V. Differences in the mechanism of antinociceptive action of non-steroidal anti-inflammatory drugs in the rat. Pharm. Sci. 2:1996;189-190.
15. Lorenzetti B.B., Ferreira S.H. Activation of the arginine-nitric oxide pathway in primary sensory neurons contributes to dipyrone-induced spinal and peripheral analgesia. Inflammation Res. 45:1996;308-311.
16. Malmberg A.B., Yaksh T.L. Antinociceptive actions of spinal non-steroidal anti-inflammatory agents on the formalin test in the rat. J. Pharmacol. Exp. Ther. 263:1992;136-146.
17. Menassé R., Hedwall P.R., Kraetz J., Pericin C., Riesterer L., Sallmann A., Ziel R., Jaques R. Pharmacological properties of diclofenac sodium and its metabolites. Scand. J. Rheumatol., Suppl. 22:1978;5-16.
18. Mixcotal-Zecuatl T., Aguirre-Bañuelos P., Granados-Soto V. Sildenafil produces antinociception and increases morphine antinociception in the formalin test. Eur. J. Pharmacol. 400:2000;81-87.
19. Moreland R.B., Goldstein I., Kim N.N., Traish A. Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor: research and clinical implications in erectile dysfunction. Trends Endocrinol. Metab. 10:1999;97-104.
20. Noguchi Y., Ishiko J., Ohtsuki I. Comparative pharmacological profiles of piroxicam, indomethacin, phenylbutazone, diclofenac, ibuprofen, and mefenamic acid. R. Soc. Med. Int. Congr. Symp. Ser. 67:1984;61-67.
21. Pyne N.J., Arshvsky V., Lochhead A. cGMP signal termination. Biochem. Soc. Trans. 24:1996;1019-1022.
22. Reyes-García G., Medina-Santillán R., Terán-Rosales F., Mateos-García E., Castillo-Henkel C. Characterization of the potentiation of the antinociceptive effect of diclofenac by vitamin B complex in the rat. J. Pharmacol. Toxicol. Methods. 42:1999;73-77.
23. Scholer D.W., Ku E.C., Boettcher I., Schweizer A. Pharmacology of diclofenac sodium. Am. J. Med. 80(Suppl. 4B):1986;34-38.
24. Sengupta S., Velpandian T., Sapra P., Mathur P., Gupta S.K. Comparative analgesic efficacy of diclofenac and nimesulide after topical application on the skin. Skin Pharmacol. Appl. Skin Physiol. 11:1998;273-278.
25. Stacher G., Steinringer H., Schneider S., Mittelbach G., Winklehner S. Experimental pain induced by electrical and thermal stimulation of the skin in healthy man: sensitivity to 75 and 150 mg diclofenac sodium in comparison with 60 mg codeine and placebo. Br. J. Clin. Pharmacol. 21:1986;35-43.
26. Takashima T., Kado Y., Ono T. Anti-inflammatory effects of GP-45,840. Clin. Rep. 6:1972;50-57.
27. Terrett N.K., Bell A.S., Brown D., Ellis P. Sildenafil (Viagra™), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg. Med. Chem. Lett. 6:1996;1819-1824.
28. Todd P.A., Sorkin E.M. Diclofenac sodium: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 35:1988;244-285.
29. Tonussi C.R., Ferreira S.H. Mechanism of diclofenac analgesia: direct blockade of inflammatory sensitization. Eur. J. Pharmacol. 251:1994;173-179.
30. Torres-López J.E., López-Muñoz F.J., Castañeda-Hernández G., Granados-Soto V. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of diclofenac in the rat. J. Pharmacol. Exp. Ther. 282:1997;685-690.